摘要：NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Small Cell Lung Cancer, Version 2.2025.

参考文献（向上滑动查看）：

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Small Cell Lung Cancer, Version 2.2025.

2. Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. J Clin Oncol. 2024 Jul 10;42(20):e44-e59.

3. Hendriks LE, Kerr KM, Menis J, et al. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357.

4. Michael Offin, Jia Luo, Robin Guo, et al. CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.[J] .JCO Precis Oncol, 2020, 4: 0.

5. Editorial Office of Chinese Journal of Lung Cancer,[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation].[J] .Zhongguo Fei Ai Za Zhi, 2023, 26: 416-428.

6. Marks JA, Gandhi N, Halmos B, et al. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology. Lung Cancer. 2024;196:107935.

7. Mazieres J, Vioix H, Pfeiffer BM, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes [published online ahead of print, 2023 Jun 18]. Clin Lung Cancer. 2023;S1525-7304(23)00126-2.

8. Yi-Long Wu, et al. Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study. 2022 ESMO AISA, 388P.

9. Wolf Jürgen, Seto Takashi ,Han Ji-Youn, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.[J] .N Engl J Med, 2020, 383: 944-957.

10. Wolf Jürgen, Hochmair Maximilian, Han Ji-Youn, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.[J] .Lancet Oncol, 2024, 25: 1357-1370.

11. Grande Enrique, Giovannini Monica, Marriere Eddie, et al. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.[J] .Br J Clin Pharmacol, 2021, 87: 2867-2878.

12. Pan Kelsey, Concannon Kyle, Li Jing, et al. Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.[J] .Nat Rev Clin Oncol, 2023, 20: 716-732.

13. Edward B. Garon, et al. Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM), 2020 AACR Abstract CT082.

14. Illini O, Fabikan H, Swalduz A, et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;14:17588359221103206.

15. Xinhui Chen, Xiaoming Cui, Nathalie Pognan, et al. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.[J] .Br J Clin Pharmacol, 2021, 88: 0.

16. 简明处方：https://www.medlive.cn/recommond.php?kyprojectid=1_002094401_1&hash=DaGO1J

17. Mazieres Julien, Paik Paul K, Garassino Marina C, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.[J] .JAMA Oncol, 2023, 9: 1260-1266.

18. Jin-Ji Yang, et al. Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations. 2023 ESMO, 1379P.

19. Terufumi, Kato,James Chih-Hsin, Yang,Myung-Ju, Ahn et al. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.[J] .Br J Cancer, 2024, 130: 0.

20. Yongfeng Yu, Jianya Zhou, Xingya Li, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.[J] .EClinicalMedicine, 2023, 59: 0.

21. Shun Lu, Jian Fang, Xingya Li, et al. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations.[J] .JTO Clin Res Rep, 2022, 3: 0.

22. CSCO非小细胞肺癌诊疗指南（2024版）.

撰写：Shirley

审校：Shirley

排版：Babel

执行：Uni

来源：医脉通肿瘤科